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Background: Contrast-induced nephropathy (CIN) is a known complication of percutaneous coronary intervention (PCI). The Mehran Risk Score 
(MRS) is a model used to predict CIN, but it has not been externally validated.
Methods: We sought to validate the MRS for prediction of CIN (defined as an increase in serum creatinine of 25% or 0.5 mg/dL over baseline 
48 hours post-PCI), hemodialysis (HD) one month after PCI, and all-cause mortality one year after PCI. Records of adult patients who underwent 
PCI at three academic medical centers in 2005 were reviewed. Patients with acute myocardial infarction, end-stage renal disease, and contrast 
exposure within one week of PCI were excluded. The MRS incorporates eight predictors: hypotension, intra-aortic balloon pump, congestive heart 
failure, chronic kidney disease, diabetes mellitus, age > 75 years, anemia, and contrast volume. MRS was calculated for each patient and stratified 
into four groups: MRS 0-5 (group 1), 6-10 (group 2), 11-15 (group 3), and 16+ (group 4). Likelihood ratios (LR) were calculated to assess the MRS 
discrimination.
Results: 931 consecutive patients were included. The overall incidence of CIN, HD, and mortality were 12.2%, 0.4%, and 9.0%, respectively. See 
the attached table for results stratified by MRS group. Increasing MRS was strongly associated with development of CIN and mortality (p < 0.01 for 
trend).
Conclusions: The MRS strongly predicted CIN and one year all-cause mortality post-PCI in this multicenter external validation study.
Incidence and Likelihood Ratios of CIN, HD, and Mortality Stratified by Mehran Risk Score Group
MRS Group 1 MRS Group 2 MRS Group 3 MRS Group 4
Incidence of CIN 5.7% 13.1% 30.7% 50%
Incidence of HD 0% 0.4% 0.9% 7.7%
Incidence of Mortality 3.4% 8.1% 29.8% 38.5%
LR for CIN 0.4 1.1 3.2 7.2
LR for HD 0 0.8 2.1 19.3
LR for Mortality 0.3 0.9 4.3 6.3
